Maximize Your Success in Decentralized Trials with SphygmoCor® Technology
ATCOR Chief Medical Officer Steven Kesten, MD discusses how to maximize success in decentralized clinical trials. For products targeting cardiovascular disease, incorporation of central aortic blood pressure (BP) measurement and monitoring can improve key decisions during development (go/no go, endpoints, population characteristics, benefit-risk profile, dosing, etc.) and enhance the likelihood of both regulatory and commercial success. The presentation reviews noninvasive central blood pressure measurement and the rationale for use in drug and medical device development programs.
Central Blood Pressure Can Effectively Predict Cardiovascular Risk!
“ We need simple individualized guidelines based on central pressure. ”
“ Precise measurement of cBP improves patient management decisions in hypertension. ”
—Lancet Commission on Hypertension
“ I use SphygmoCor in my preventive cardiology practice—it’s an integral component of my cardiovascular risk assessment. ”
—Lee Marcus MD, MS, FACC
What's new in Central Blood Pressure?
Managing Hypertension With Central Blood Pressure Insights
The only cure for dementia is prevention.
Central blood pressure (cBP) and arterial stiffness may be early indicators of Alzheimer’s and other causes of dementia.1,2
ATCOR noninvasive central blood pressure and pulse wave analysis enable clinicians to identify high-risk patients and target therapies to delay or prevent dementia.
SphygmoCor® by the numbers
All “Top 20 Hospitals” use SphygmoCor® technology to measure central blood pressure (cBP)
4,000+ studies using the SphygmoCor® technology have been published in peer-reviewed clinical publications.
8 out of Top 10 Pharma companies have used SphygmoCor® technology in their clinical trials
Over 11,000 patients have been tested with SphygmoCor® technology in pharmaceutical trials